Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 43 Rectal Neoplasms 12 Colonic Neoplasms 12 Neoplasm Metastasis 6 Stomach Neoplasms 5 Pancreatic Neoplasms 5 Gallbladder Neoplasms 3 Colorectal Cancer Metastatic 3 Cholangiocarcinoma 3 Neutropenia 2 Neoplasms 2 Bile Duct Neoplasms 2 Adenocarcinoma 2 mCRC 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Solid Tumor 1 Recurrence 1 Pretreated Metastatic Colorectal Cancer 1 Neuroendocrine Tumors 1 Neuroectodermal Tumors, Primitive 1 Nasopharyngeal Carcinoma 1 Microsatellite-stable Colorectal Cancer 1 Metastatic Gastric Adenocarcinoma 1 High-grade Extra Pulmonary Neuroendocrine Cancer 1 Gastrointestinal Neoplasms 1 Gastrointestinal Diseases 1 Gastric and Gastroesophageal Junction Adenocarcinoma 1 Gastric Cancer Adenocarcinoma Metastatic 1 Gastric Adenocarcinoma 1

Interventions

trifluridine tipiracil drug combination 1 lenvatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × First-line Treatment × trifluridine tipiracil drug combination × Clear all

NCT05077839 2021-10-25

TOBACO

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown

Gastrointestinal

First-line Treatment

Data powered by HemOnc (CC BY 4.0) Colophon ⚡